Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$258.00-0.81%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Achieve $4.9B-$5.3B revenue in 2026: FY26 revenue guidance $4.2B-$4.5B vs $4.9B-$5.3B target.
Alnylam aims for $4.9B to $5.3B revenue in 2026, showing strong growth. Partnerships and new RNAi therapies support expanding sales. The company controls costs with R&D and SG&A expenses targeted at $2.7B to $2.8B. Recent earnings beats and strategic deals reinforce growth prospects.
Revenue growth may slow below targets amid recent guidance cuts. Cost control efforts might not offset pressure on margins. Insider selling and analyst downgrades raise concerns about confidence and outlook.
The market prices in about 57% revenue growth and values shares slightly above our fair value estimate near $319. Our fair value is below the Street median, reflecting more cautious expectations. We differ by emphasizing risks from recent guidance cuts and cost pressures.
Breaks if: expenses exceed $2.8B in FY26
Breaks if: no new partnerships or partnership contractions over next year
Breaks if: revenue falls below $4.9B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. ALNY is navigating a challenging environment with elevated risks, but its recent financial performance has been strong, indicating potential for future growth.
The market seems to have priced in a justified valuation, but it is considered expensive compared to its peers. There is a negative expectations gap, suggesting that some investors may be cautious about future performance.
Management is on track to achieve its revenue and expense targets for 2026, despite a recent earnings miss. The growth in total TTR revenues shows strong demand, but the lowered guidance reflects a more cautious outlook.
The thesis hinges on whether ALNY can raise guidance in the next quarter and if the broader healthcare sector continues to perform well. Additionally, macroeconomic factors, such as job growth, could impact sentiment and performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports revenue growth for the TTR franchise. However, guidance cuts raise concerns about achieving revenue targets for 2026.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Alnylam aims to achieve total net product revenues between $4.9 billion and $5.3 billion for the fiscal year 2026.
Over the next 1-3 years, ALNY's performance will depend on its ability to manage expectations and navigate industry challenges. Not investment advice.